Anacor Pharmaceuticals, Inc.
) enrolled the first patient in a phase III study on its atopic
dermatitis candidate, AN2728, for the topical treatment of
mild-to-moderate atopic dermatitis.
The phase III trials comprise two multi-center, double-blind,
), placebo-controlled studies enrolling roughly 750 patients (two
years and above) each.
An Investigator Static Global Assessment (ISGA) is a 5-point
scale from 0 (clear) to 4 (severe). An ISGA score of 2 or 3
represents mild-to-moderate atopic dermatitis. The primary
endpoint is to achieve an ISGA score of 0 or 1 with at
least a 2-grade improvement from baseline on Day 29. Secondary
endpoints include achieving an ISGA score of 0 or 1 at Day
29 along with the time to treatment success.
A long-term safety study will also be conducted by Anacor to
evaluate the safety of intermittent use of AN2728 for a period of
12 months. Patients who complete either of the two phase III
studies may enroll in this study.
We note that Anacor expects a response regarding its most
advanced candidate Kerydin for the treatment of onychomycosis to
be out by Jul 29, 2014. Anacor intends to launch Kerydin in the
second half of 2014 assuming U.S. Food and Drug Administration
Anacor carries a Zacks Rank #3 (Hold). We are encouraged by
the pipeline progress at Anacor. However, the atopic dermatitis
market is crowded with drugs like Elidel and Protopic. We also
Regeneron Pharmaceuticals, Inc.
) are evaluating dupilumab for treating patients suffering from
moderate-to-severe atopic dermatitis.
Investors looking for better-ranked stocks may consider a
Zacks Rank #1 (Strong Buy) company like
ANACOR PHARMACT (ANAC): Free Stock Analysis
REGENERON PHARM (REGN): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.